Friday, June 28, 2019 2:46:28 PM
St. Jude Children’s Research Hospital scientists studying the immune response to brain tumors have identified a pathway that clears a toxic protein that is a hallmark of Alzheimer’s disease.
St. Jude Children’s Research Hospital scientists have discovered a pathway that functions like a car wash to prevent the buildup of a toxic protein associated with Alzheimer’s disease. The report appeared online today in the journal Cell.
The findings in a mouse model of Alzheimer’s offer a possible new approach to treatment of the chronic neurodegenerative disorder, which is the sixth leading cause of death in the U.S. The newly identified pathway also helps regulate inflammation, so the discovery could yield strategies for unleashing the immune response against malignant brain tumors.
Researchers called the pathway LC3-associated endocytosis or LANDO. They found the pathway in microglial cells, the primary immune cells of the brain and central nervous system. However, preliminary evidence suggests LANDO is a fundamental process that functions in cells throughout the body.
Lando pathway – sufficient
B-amyloid (red) in a brain that is LANDO-sufficient.
Investigators showed that LANDO protected against deposits of neurotoxic ß-amyloid protein in mice. Activation of the pathway also guarded against toxic neuroinflammation and neurodegeneration, including memory problems.
“In the context of neurodegenerative diseases such as Alzheimer’s, activating LANDO in microglial cells could prove to be therapeutically beneficial through increased clearance of ß-amyloid and mitigation of neuroinflammation,” said corresponding author Douglas Green, Ph.D., chair of the St. Jude Department of Immunology.
While activation of LANDO appears to protect against neurodegenerative disease, first author Bradlee Heckmann, Ph.D., a postdoctoral fellow in Green’s laboratory, said inhibiting the pathway might boost the effectiveness of cancer immunotherapy. “Although in its infancy, preliminary data using a primary brain tumor model suggests that inhibition of LANDO might provide a mechanism to activate inflammation within the tumor microenvironment to generate an anti-tumor response,” Heckmann said.
Car wash
ß-amyloid protein accumulation in neurons is a hallmark of Alzheimer’s. Scientists knew microglial cells take up ß-amyloid proteins. Discovery of the LANDO pathway answers questions about what comes next.
Heckmann compared LANDO to the operator of an automatic carwash. In this case, the cars are the receptors on the microglial cells that bind to neurotoxic ß-amyloid proteins and bring the protein into the car wash. And, just as cars return to the streets after the dirt is gone, when the ß-amyloid is disposed of, the receptor returns to the microglial surface where it can pick up additional ß-amyloid.
Read the full text of the article:
“LC3-associated endocytosis facilitates -amyloid clearance and mitigates neurodegeneration in murine Alzheimer’s Disease.”
Cell. Published online: June 27, 2019
An automatic car wash depends on hardware to attach the car to a track that moves it through the machine. Similarly, several proteins are required for LANDO functioning. The proteins—Rubicon, Beclin 1, ATG5 and ATG7—are better known for their roles in a related cell pathway used to recycle unneeded and unwanted cell components. These proteins decline with age as their expression decreases.
Follow the data
“You never know where science will lead,” Green said. “This project started because we were studying immune responses against cancer. Brad recognized the findings had relevance to a disease not of children but of older people.
“That’s how science works. When you follow the data, you never know where it will lead.”
The other authors are Brett Teubner, Bart Tummers, Emilio Boada-Romero, Lacie Harris, Mao Yang, Clifford Guy and Stanislav Zakharenko, all of St. Jude.
The research was funded in part by grants (AI40646, CA231620, AI138492, CA231423) from the National Institutes of Health; the Lupus Research Alliance; the John H. Sununu Endowed Fellowship; the Paul Barrett Endowed Fellowship; and ALSAC, the fundraising and awareness organization of St. Jude.
https://www.stjude.org/media-resources/news-releases/2019-medicine-science-news/lando-pathway-prevents-alzheimers-protein-buildup.html
DIFFERENT STROKES FOR DIFFERENT FOLKS
DIFFERENT STROKES FOR DIFFERENT FOLKS
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
